Practical approach to management of chronic lymphocytic leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10326696" target="_blank" >RIV/00179906:_____/16:10326696 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/16:10326696

Výsledek na webu

<a href="http://dx.doi.org/10.5114/aoms.2016.55424" target="_blank" >http://dx.doi.org/10.5114/aoms.2016.55424</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5114/aoms.2016.55424" target="_blank" >10.5114/aoms.2016.55424</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Practical approach to management of chronic lymphocytic leukemia

Popis výsledku v původním jazyce

Revolutionary progress has recently changed the landscape of chronic lymphocytic leukemia (CLL). Powerful prognostic factors, especially p53 mutation and/or deletion and IGHV mutation status, have refined individual patient prognosis. Purine analogs and monoclonal antibodies paved the way from palliative treatment to chemoimmunotherapy capable of eradication of minimal residual disease and prolongation of survival. Obinutuzumab (GA-101) and ofatumumab have been recently approved for the treatment of comorbid patients. Bendamustine is available for first-line treatment of patients ineligible for fludarabine, cyclophosphamide, and rituximab (FCR). High-dose glucocorticoids combined with rituximab represent a promising option for refractory CLL; ofatumumab is approved for fludarabine-and alemtuzumab-refractory patients. Allogeneic stem cell transplantation is the only curative option but is feasible in a highly selected group of patients only. The novel small molecule inhibitors ibrutinib and idelalisib have been recently approved for relapsed/refractory CLL This review provides practical advice for diagnosis, prognostication and treatment of CLL

Název v anglickém jazyce

Practical approach to management of chronic lymphocytic leukemia

Popis výsledku anglicky

Revolutionary progress has recently changed the landscape of chronic lymphocytic leukemia (CLL). Powerful prognostic factors, especially p53 mutation and/or deletion and IGHV mutation status, have refined individual patient prognosis. Purine analogs and monoclonal antibodies paved the way from palliative treatment to chemoimmunotherapy capable of eradication of minimal residual disease and prolongation of survival. Obinutuzumab (GA-101) and ofatumumab have been recently approved for the treatment of comorbid patients. Bendamustine is available for first-line treatment of patients ineligible for fludarabine, cyclophosphamide, and rituximab (FCR). High-dose glucocorticoids combined with rituximab represent a promising option for refractory CLL; ofatumumab is approved for fludarabine-and alemtuzumab-refractory patients. Allogeneic stem cell transplantation is the only curative option but is feasible in a highly selected group of patients only. The novel small molecule inhibitors ibrutinib and idelalisib have been recently approved for relapsed/refractory CLL This review provides practical advice for diagnosis, prognostication and treatment of CLL

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13412" target="_blank" >NT13412: Komplexní hodnocení vlivu mikroprostředí na klinický průběh chronické lymfocytární leukémie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Archives of Medical Science

ISSN

1734-1922

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

9

Strana od-do

448-456

Kód UT WoS článku

000374510200028

EID výsledku v databázi Scopus

2-s2.0-84963768974